🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523832-38-00
Authorised Phase III

Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone

2025-523832-38-00 · tracked via the Priya Life Science EU tracker
Sponsor
Schneider Children's Medical Center Of Israel
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Musculoskeletal Diseases
Decision date
23/06/2026
Enrollment target
95
Sites
Greece, Poland, France, Czechia

Condition studied

Small for gestational age (SGA) and idiopathic short stature (ISS)

Investigational medicinal product(s)

GENOTROPIN 12 mg powder and solvent for solution for injection.Ngenla 60 mg solution for injection in pre-filled pen

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

Annualized HV after 12 months of treatment

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523832-38-00 on CTIS ↗ ← All trials in the EU